90 related articles for article (PubMed ID: 2870898)
1. Metabolism of unsaturated derivatives of valproic acid in rat liver microsomes and destruction of cytochrome P-450.
Prickett KS; Baillie TA
Drug Metab Dispos; 1986; 14(2):221-9. PubMed ID: 2870898
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.
Rettie AE; Rettenmeier AW; Howald WN; Baillie TA
Science; 1987 Feb; 235(4791):890-3. PubMed ID: 3101178
[TBL] [Abstract][Full Text] [Related]
4. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA
Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383
[TBL] [Abstract][Full Text] [Related]
5. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
[TBL] [Abstract][Full Text] [Related]
6. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes.
Porubek DJ; Grillo MP; Baillie TA
Drug Metab Dispos; 1989; 17(2):123-30. PubMed ID: 2565201
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies.
Rettie AE; Boberg M; Rettenmeier AW; Baillie TA
J Biol Chem; 1988 Sep; 263(27):13733-8. PubMed ID: 3138238
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes.
Kassahun K; Hu P; Grillo MP; Davis MR; Jin L; Baillie TA
Chem Biol Interact; 1994 Mar; 90(3):253-75. PubMed ID: 8168173
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the in vitro metabolism of allylisopropylacetamide to reactive intermediates. Mechanistic studies with oxygen-18.
Prickett KS; Baillie TA
Biomed Mass Spectrom; 1984 Jul; 11(7):320-31. PubMed ID: 6478043
[TBL] [Abstract][Full Text] [Related]
11. Heme enhances hexobarbital metabolism in perfused rat liver after drug-mediated destruction of cytochrome P-450.
Farrell GC; Gollan JL; Correia MA; Schmid R
J Pharmacol Exp Ther; 1981 Aug; 218(2):363-7. PubMed ID: 7252836
[TBL] [Abstract][Full Text] [Related]
12. P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.
Fisher MB; Thompson SJ; Ribeiro V; Lechner MC; Rettie AE
Arch Biochem Biophys; 1998 Aug; 356(1):63-70. PubMed ID: 9681992
[TBL] [Abstract][Full Text] [Related]
13. Destruction of cytochrome P-450 by 2-isopropyl-4-pentenamide and methyl 2-isopropyl-4-pentenoate: mass spectrometric characterization of prosthetic heme adducts and nonparticipation of epoxide metabolites.
Ortiz de Montellano PR; Yost GS; Mico BA; Dinizo SE; Correia MA; Kumbara H
Arch Biochem Biophys; 1979 Oct; 197(2):524-33. PubMed ID: 41487
[No Abstract] [Full Text] [Related]
14. Metabolism of valproic acid by hepatic microsomal cytochrome P-450.
Prickett KS; Baillie TA
Biochem Biophys Res Commun; 1984 Aug; 122(3):1166-73. PubMed ID: 6433908
[TBL] [Abstract][Full Text] [Related]
15. Delta 2-valproate biotransformation using human liver microsomal fractions.
Fabre G; Briot C; Marti E; Montseny JP; Bourrié M; Massé D; Berger Y; Cano JP
Pharm Weekbl Sci; 1992 Jun; 14(3A):146-51. PubMed ID: 1502016
[TBL] [Abstract][Full Text] [Related]
16. In vitro hydroxylation and epoxidation of some isomeric lauric acid analogs by rat liver microsomes. Identification of metabolites and effects of clofibrate or phenobarbital pretreatment.
Boucher JL; Delaforge M; Salaün JP; Pinot F; Durst F; Pflieger P; Mioskowski C
Drug Metab Dispos; 1996 Apr; 24(4):462-8. PubMed ID: 8801062
[TBL] [Abstract][Full Text] [Related]
17. [Resistance of different forms of rat liver cytochrome P-450 to influence destabilizing microsomal membranes].
Gromova OA; Zakharova NE; Liakhovich VV; Tsyrlov IB
Biull Eksp Biol Med; 1977 May; 83(5):553-5. PubMed ID: 884258
[TBL] [Abstract][Full Text] [Related]
18. Metabolic conversion of 2-propylpentanal acetals to valproic acid in vitro. Model prodrugs of carboxylic acid agents.
Vicchio D; Callery PS
Drug Metab Dispos; 1989; 17(5):513-7. PubMed ID: 2573494
[TBL] [Abstract][Full Text] [Related]
19. NADPH-dependent microsomal metabolism of 14,15-epoxyeicosatrienoic acid to diepoxides and epoxyalcohols.
Capdevila JH; Mosset P; Yadagiri P; Lumin S; Falck JR
Arch Biochem Biophys; 1988 Feb; 261(1):122-33. PubMed ID: 3341770
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional reconstitution of hepatic cytochrome P-450 in vivo. Reversal of allylisopropylacetamide-mediated destruction of the hemoprotein by exogenous heme.
Farrell GC; Correia MA
J Biol Chem; 1980 Nov; 255(21):10128-33. PubMed ID: 7430117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
